NEW YORK, October 8, 2013—Kantar Health, a leading global healthcare consulting firm, will host an Oncology Insights workshop on October 24, 2013, at the Royal College of Physicians, Regent’s Park, in London. The workshop will bring together scientific and research expertise to discuss the most recent developments in oncology and their implications for the UK pharmaceutical industry, providing an opportunity for a candid, mutual exchange of opinions and ideas.
The seminar will be led by Richard Goosey, Chief Methodologist, Advanced Methods at Kantar Health. It will include three sessions:
- Oncology Conference Insights: Implications for Recent Clinical Developments. Richard Wagner, Ph.D., Vice President, Commercial Planning, will highlight implications of the most recent drug approvals and clinical results on the oncology competitive landscape.
- Oncology Market Access: Developments. Andrew Miniuks, Senior Director, Commercial Planning, will discuss recent developments affecting UK oncology market access, including the implementation of the Health and Social Care Bill and the development of the NHS Commissioning Board.
- Launch Excellence in Oncology. Elisabeth Roscher-Nielsen, Senior Business Director, and Mr. Goosey will focus on pre-Phase III research issues, including design of Phase III clinical trials and finalizing the TPP, and post-Phase III research issues, including positioning and messaging and KPI tracking at launch.
The presentations will start at 10 a.m., and a Q&A session will follow the presentations. To register, contact Suzy Ager.
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.